L’annonce d’un décès à la famille : vécu des internes de médecine générale et perspectives d’amélioration. Une étude qualitative par entretiens semi structurés.

International audienc

Attitudes of family physicians towards adolescent cannabis users: a qualitative study in France

International audienc

Dépistage de la broncho-pneumopathie chronique obstructive par minispirométrie électronique en médecine générale

International audienc

Étude comparative en soins primaires du taux d'INR dans la cible thérapeutique chez des patients traités par warfarine ou fluindione pour une fibrillation atriale. L’étude FLOWER (FLuindione Or WarfarinE – Result INR)

International audienc

Accuracy of human sperm DNA oxidation quantification and threshold determination using an 8-OHdG immuno-detection assay

International audienc

Apport de l’imagerie par résonance magnétique au diagnostic du mésothéliome péricardique : à propos d’un cas

International audienc

Direct Medical Costs of Type 2 Diabetes in France: An Insurance Claims Database Analysis

International audienceObjectives: Our objects was to estimate the direct healthcare costs of type 2 diabetes mellitus (T2DM) in France in 2013.Methods: Data were drawn from a random sample of ≈600,000 patients registered in the French national health insurances database, which covers 90% of the French population. An algorithm was used to select patients with T2DM. Direct healthcare costs from a collective perspective were derived from the database and compared with those from a control group to estimate the cost of diabetes and related comorbidities. Overall direct costs were also compared according to the diabetes therapies used throughout the year 2013.Results: Cost analysis was available for a sample of 25,987 patients with T2DM (mean age 67.5 ± standard deviation 12.5; 53.9% male) matched with a control group of 76,406 individuals without diabetes. Overall per patient per year medical expenditures were €6506 ± 10,106 in the T2DM group as compared with €3668 ± 6954 in the control group. The cost difference between the two groups was €2838 per patient per year, mainly due to hospitalizations, medication and nursing care costs. Total per capita annual costs were lowest for patients receiving metformin monotherapy (€4153 ± 6170) and highest for those receiving insulin (€12,890). However, apart from patients receiving insulin, costs did not differ markedly across the different oral treatment patterns.Conclusion: Extrapolating these results to the whole T2DM population in France, total direct costs of diagnosed T2DM in 2013 was estimated at over €8.5 billion. This estimate highlights the substantial economic burden of this condition on society